依普利酮治疗高血压患者的效果怎么样呢？

For the treatment of congestive heart failure after acute myocardial infarction and the treatment of hypertension.

What is the effect of eplerenone in treating patients with hypertension? 

The clinical trial uses losartan as a reference to evaluate the clinical efficacy and safety of eplerenone tablets in the treatment of mild to moderate essential hypertension. Methods: 72 patients with mild to moderate hypertension were randomly divided into: ambulatory blood pressure group, losartan group, and eplerenone group, with 24 cases in each group. The losartan group and the eplerenone group used a double-simulation and positive drug parallel control method, and received losartan and eplerenone treatment respectively. After 4 weeks of treatment, if the blood pressure did not reach the target, the drug dose was doubled and the treatment continued for 4 weeks; if the blood pressure reached the target, the original dose was maintained and the treatment continued for 4 weeks. The ambulatory blood pressure group took 25 mg of eplerenone, once a day.

The results showed that after 8 weeks of treatment, compared with before treatment, the average sitting diastolic blood pressure of the eplerenone group decreased by (13.32±4.57) mmHg, and that of the losartan group decreased by (10.90±5.64) mmHg. The difference between the two groups was not statistically significant. After 8 weeks of treatment, compared with before treatment, the average sitting systolic blood pressure of the eplerenone group decreased by (23.56±9.39) mmHg, and that of the losartan group decreased by (18.67±7.00) mmHg. There was no statistically significant difference between the two groups; the average sitting systolic blood pressure of the eplerenone group and the losartan group reached the standard. The antihypertensive effective rates were 83.33% and 91.30% respectively, with no statistically significant difference between the two groups; the antihypertensive effective rates were 75.0% and 60.9%, respectively, and the total antihypertensive effective rates were 91.7% and 91.3%, respectively. There was no statistically significant difference between the two groups in the antihypertensive effective rate and total antihypertensive effective rate.

Eplerenone adverse reactions: >10% Endocrine and metabolic: hyperkalemia, heart failure, post-myocardial infarction, hypertension, hypertriglyceridemia (1%-15%; dose related). Adverse Reactions >10% Endocrine and Metabolic: Hyperkalemia ([Heart failure, post-myocardial infarction: >5.5meq/L: 16%; ≥6meq/L: 6%, [Hypertension, >5.5meq/L: 400mg: 9%; dose ≤200mg: ≤1%]), hypertriglyceridemia (1%-15%; dose related). 1%-10% Central nervous system: dizziness, fatigue. Endocrinology and Metabolism: Hyponatremia (2%; dose-related), proteinuria, gynecomastia, hypercholesterolemia. Gastrointestinal tract: diarrhea, abdominal pain. Genitourinary system: abnormal vaginal bleeding, breast pain (males: ≤1%). Renal: Increased serum creatinine (heart failure, post-myocardial infarction: 6%). Respiratory system: Cough, flu-like symptoms. <1% post-marketing or case reports: angioedema, increased blood urea nitrogen, increased liver enzymes, increased uric acid, rash.